Preoperative application of Parecoxib can alleviate postoperative pain of early esophageal cancer after ESD by reducing inflammatory response

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080433

Enrollment

Unknown

Registered

2024-01-29

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Observation group:The observation group received intravenous injection of parecoxib 40mg 30 min before surgery

Control group:The control group received the same volume of normal saline.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) meet the surgical indications of endoscopic submucosal dissection; (2) able to communicate normally; (3) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with nervous system, chronic pain or mental illness who use psychiatric drugs or analgesics for a long time; (2) patients with obvious abnormal liver and kidney function or cardiovascular and cerebrovascular diseases; (3) long history of drug use or abuse; (4) pregnant or lactating women; (5) parecoxib allergic patients; (6) contraindications to the study protocol.

Design outcomes

Primary

Measure	Time frame
Postoperative pain;Serum C-reactive protein;Interleukin-6;white blood cell count;	—

Countries

China

Contacts

Public ContactGao,yuanjun

Shiyan Taihe hospital

985059559@qq.com+86 13 636 220 1847

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 16, 2026